论文部分内容阅读
目的研究替吉奥胶囊辅助放疗对贲门癌患者远期预后的影响。方法选取2013年12月至2015年12月贲门癌患者94例,抽签随机分为观察组和对照组,每组47例。观察组给予替吉奥胶囊辅助放疗治疗,对照组给予单纯放疗治疗,比较两组患者消化道不良反应、骨髓抑制情况、治疗耐受性和近期疗效,随访1年记录两组患者的生存率。结果治疗后观察组治疗有效率为89.36%,显著高于对照组的74.47%(P<0.05);观察组出现放射性食管炎、胃炎、骨髓抑制等主要不良反应的发生率为70.21%,高于对照组的59.57%,但差异未见统计学意义(P>0.05),且对症处理后主要不良反应症状均获得不同程度的缓解,患者均可耐受治疗;随访1年后,观察组病死率为4.26%,显著低于对照组的17.02%(P<0.05)。结论替吉奥胶囊辅助放疗治疗贲门癌,患者主要不良反应虽稍高于单纯放疗治疗,但不良反应可耐受,治疗有效率更高,患者的生存率明显提高,具有一定的临床疗效,值得临床应用推广。
Objective To study the long-term prognosis of gastric cardia cancer patients treated with adjuvant radiotherapy. Methods 94 patients with cardia cancer from December 2013 to December 2015 were randomly selected. The randomized patients were divided into observation group and control group, with 47 patients in each group. The patients in the observation group were given adjuvant radiotherapy for Tigao capsule and the control group were treated with radiotherapy alone. The gastrointestinal adverse reactions, bone marrow suppression, treatment tolerance and short-term curative effect were compared between the two groups. The survival rate of the two groups was followed up for one year. Results After treatment, the effective rate of observation group was 89.36%, which was significantly higher than that of control group (74.47%, P <0.05). The incidence of major adverse reactions such as esophagitis, gastritis and myelosuppression in observation group was 70.21% (59.57%) in the control group, but the difference was not statistically significant (P> 0.05), and the symptomatic treatment of major adverse reactions were relieved to varying degrees, patients can be tolerated treatment; follow-up 1 year after the observation group mortality 4.26%, significantly lower than the control group 17.02% (P <0.05). Conclusions The main side effects of TIGO capsule radiotherapy for cardia cancer are slightly higher than that of radiotherapy alone, but the adverse reactions are tolerable, the treatment is more efficient, the survival rate of patients is obviously improved, and the clinical effect is worthwhile Clinical application promotion.